Financing Pharmaceutical Innovation : How Much Should Poor Countries Contribute?
A public economics framework is used to consider how pharmaceuticals should be priced when at least some of the research and development incentive comes from sales revenues. Familiar techniques of public finance are used to relax some of the restri...
| Main Authors: | , |
|---|---|
| Format: | Journal Article |
| Language: | English en_US |
| Published: |
Published by Oxford University Press on behalf of the World Bank
2014
|
| Subjects: | |
| Online Access: | http://documents.worldbank.org/curated/en/2005/01/17747581/financing-pharmaceutical-innovation-much-poor-countries-contribute http://hdl.handle.net/10986/16481 |
| Summary: | A public economics framework is used to
consider how pharmaceuticals should be priced when at least
some of the research and development incentive comes from
sales revenues. Familiar techniques of public finance are
used to relax some of the restrictions implied in the
standard use of Ramsey pricing. Under the more general
model, poor countries should not necessarily cover even
their own marginal costs, and the pricing structure is not
related to that which will be chosen by a monopolist in a
simple way. This framework is then used to examine ongoing
debates regarding the international patent system as
embodied in the world trade organization's agreement on
trade-related aspects of intellectual property rights. |
|---|